Parabilis Medicines announced an oversubscribed $305 million financing to support FOG-001 clinical development and its pipeline.
- Amount
- $305M
- Announced
- 8 January 2026
- Leads
- RA Capital Management, Fidelity Management & Research Company, Janus Henderson Investors
- Other investors
- Frazier Life Sciences, Soleus Capital, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky Way Investments, GV, accounts advised by T. Rowe Price Associates, Inc.
- Use of funds
- Continue zolucatetide clinical development, including a Phase 3 desmoid tumor trial, and advance discovery pipeline.
- Checked
- Amount and date checked against the press source